Q-omics provides the consensus-scored MIR1270 profile across patient tissues and cancer cell-line models. MIR1270 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR1270 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MIR1270 RNA expression shows 10,950 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where MIR1270 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1270 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1270 survival associations across molecular data types. MIR1270 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1270 RNA expression–survival associations across cancer types. High MIR1270 expression shows unfavorable associations in DLBC, ACC, LUSC and LIHC, but favorable associations in BLCA and OV. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR1270 RNA expression.
This table summarizes MIR1270 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1270. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1270 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher MIR1270 RNA expression in tumor versus normal tissue (log2 FC = +1.764, t-test p < 0.001).
This table shows molecular features associated with MIR1270 in patient tissues and cancer cell lines. In patient samples, MIR1270 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
